KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas

• Published in: Histopathology Vol. 61; no. 6; pp. 1036 - 1042
• Main Authors: Alexander, Riley E, Lopez-Beltran, Antonio, Montironi, Rodolfo, MacLennan, Gregory T, Post, Kristin M, Bilbo, Sarah A, Jones, Timothy D, Huang, Wenbin, Rao, Qiu, Sen, Joyashree D, Meehan, Kari, Cornwell, Anita, Miravalle, Leticia, Cheng, Liang
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.12.2012; Blackwell; Wiley Subscription Services, Inc
• Subjects: Adenocarcinoma; Adenocarcinoma - classification; Adenocarcinoma - diagnosis; Adenocarcinoma - genetics; Adult; Age; Aged; Aged, 80 and over; Biological and medical sciences; Bladder; carcinogenesis; Clinical trials; Colon cancer; Data processing; Diagnosis, Differential; differential diagnosis; Differentiation; DNA; DNA, Neoplasm - genetics; Excretory system; Female; Humans; Investigative techniques, diagnostic techniques (general aspects); K-Ras protein; KRAS mutation; Male; Medical sciences; Middle Aged; Mutation; Mutation - genetics; Nucleotide sequence; Paraffin Embedding; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques; Predictive Value of Tests; Primers; Prognosis; Proto-Oncogene Proteins - genetics; Proto-Oncogene Proteins p21(ras); ras Proteins - genetics; targeted therapy; Urinary bladder; Urinary Bladder Neoplasms - classification; Urinary Bladder Neoplasms - diagnosis; Urinary Bladder Neoplasms - genetics; urothelial carcinoma; urothelial carcinoma with glandular differentiation; Adenocarcinoma; KRAS mutation; differential diagnosis; Targeted therapy; Malignant tumor; Transitional cell carcinoma; Cell differentiation; Carcinogenesis; Differential diagnostic; K ras Gene; urothelial carcinoma with glandular differentiation; Anatomic pathology; Treatment; Urinary system; Urinary bladder; C-Onc gene; Targeted drug; Primary; Genetics; Mutation; Differentiation; Protooncogene; Cancer
• ISSN: 0309-0167; 1365-2559
• DOI: 10.1111/j.1365-2559.2012.04309.x

Alexander R E, Lopez‐Beltran A, Montironi R, MacLennan G T, Post K M, Bilbo S A, Jones T D, Huang W, Rao Q, Sen J D, Meehan K, Cornwell A, Miravalle L & Cheng L 
(2012) Histopathology
KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas Aims:  To determine whether KRAS mutations occur in primary bladder adenocarcinoma. Methods and results:  Twenty‐six cases of primary urinary bladder adenocarcinoma were analysed. DNA was extracted from formalin‐fixed, paraffin‐embedded tissue and amplified with shifted termination assay technology, which recognizes wild‐type or mutant target sequences and selectively extends detection primers with labelled nucleotides. A mutation in KRAS was found in three (11.5%) of 26 primary bladder adenocarcinomas. Two of these three cases exhibited a G13D mutation, whereas the remaining case contained a mutation in G12V. None of the ten cases of urothelial carcinoma with glandular differentiation displayed KRAS mutation. Colonic adenocarcinoma contained a KRAS mutation in 18 (33%) of 55 cases. There was no distinct difference with regard to grade, stage or outcome according to the limited clinicopathological data available. However, the two youngest patients, aged 32 and 39 years, in our study group, with a mean population age of 61 years, were found to have mutations in KRAS. Conclusions:  KRAS mutations are present in a small subset of primary urinary bladder adenocarcinomas. Future clinical trials for treatment of bladder adenocarcinoma, employing targeted therapies similar to those used for treatment of colon cancer, may also benefit from the predictive implications of KRAS mutational testing.